InvestSMART

Radiopharm Theranostics Limited (ASX: RAD) - Announcements

- Current share price for RAD : $0.010

ASX company news and announcements for Radiopharm Theranostics Limited (RAD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Radiopharm Theranostics Limited (RAD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Radiopharm Theranostics Limited (RAD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Radiopharm Theranostics Limited (RAD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$43 FDA grants rare pediatric disease designation for DUNP19 16 Sep 2022 11:57AM $0.180 $0.010 fallen by 94.44%
$43 JV with MD Anderson to develop novel radiopharmaceuticals 14 Sep 2022 9:22AM $0.170 $0.010 fallen by 94.12%
$43 FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma 9 Sep 2022 8:58AM $0.170 $0.010 fallen by 94.12%
$43 Appendix 4E and Preliminary Final Report - unaudited 5 Sep 2022 11:31AM $0.165 $0.010 fallen by 93.94%
$43 Application for quotation of securities - RAD 1 Sep 2022 12:51PM $0.165 $0.010 fallen by 93.94%
$43 Appendix 4E and Preliminary Final Report 31 Aug 2022 8:47AM $0.175 $0.010 fallen by 94.29%
$43 Notification of Release of Shares from Escrow 23 Aug 2022 10:52AM $0.200 $0.010 fallen by 95%
$43 Strategic agreements with Lantheus and NanoMab 4 Aug 2022 8:55AM $0.220 $0.010 fallen by 95.45%
$43 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2022 8:35AM $0.215 $0.010 fallen by 95.35%
$43 GenesisCare agreement extended to prostate cancer trial 1 Jul 2022 9:50AM $0.150 $0.010 fallen by 93.33%
$43 Dr Susann Brady-Kalnay added to Scientific Advisory Board 21 Jun 2022 9:10AM $0.140 $0.010 fallen by 92.86%
$43 Investor webinar - RAD adds brain tumor technology 15 Jun 2022 11:45AM $0.145 $0.010 fallen by 93.10%
$43 Supply agreement with Isotopia for Lutetium-177 14 Jun 2022 10:03AM $0.145 $0.010 fallen by 93.10%
$43 Investor Presentation 9 Jun 2022 8:19AM $0.175 $0.010 fallen by 94.29%
$43 RAD adds Brain Tumor Technology to Portfolio 9 Jun 2022 8:19AM $0.175 $0.010 fallen by 94.29%
$43 Initial Director's Interest Notice - LA 6 Jun 2022 12:46PM $0.190 $0.010 fallen by 94.74%
$43 RAD Appoints Dr Leila Alland as Non-Executive Director 6 Jun 2022 9:55AM $0.185 $0.010 fallen by 94.59%
$43 Industry leader Vittorio Puppo appointed COO 1 Jun 2022 9:45AM $0.195 $0.010 fallen by 94.87%
$43 Notification regarding unquoted securities - RAD 30 May 2022 8:30AM $0.190 $0.010 fallen by 94.74%
$43 Notice Under Section 708A 27 May 2022 6:46PM $0.190 $0.010 fallen by 94.74%
$43 Application for quotation of securities - RAD 27 May 2022 6:27PM $0.190 $0.010 fallen by 94.74%
$43 RAD presentation to Bioshares Biotech Summit 12 May 2022 10:44AM $0.195 $0.010 fallen by 94.87%
$43 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2022 9:49AM $0.220 $0.010 fallen by 95.45%
$43 Virtual investor conference presentation 2 May 2022 28 Apr 2022 2:03PM $0.225 $0.010 fallen by 95.56%
$43 Change of Director's Interest Notice - PH 14 Apr 2022 5:34PM $0.230 $0.010 fallen by 95.65%

401 - 425 of 613 results

Page 17 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.